Research & DevelopmentMultiple New Chemical Entities Driving Towards New Therapies

Pharmacyclics' technology platform is based on several novel classes of small-molecule pharmaceuticals. Each is rationally designed to target cancer and/or autoimmune diseases in unique ways.

The products under development at Pharmacyclics include:

• Motexafin Gadolinium (MGd), which is under evaluation for use in patients with brain metastases from non-small cell lung cancer and other cancers.
• HDAC inhibitors, including PCI-24781, an oral compound now in Phase 1 and 2 clinical development in solid and hematologic cancers. These drugs are being developed as cancer therapies based on their ability to alter gene expression to induce tumor cell death.
• Factor VIIa inhibitor PCI-27483, a small-molecule inhibitor targeting the Factor VIIa/Tissue Factor complex that is designed to treat cancer patients by inhibiting both tumor progression and associated thrombotic disease.
• Bruton's Tyrosine Kinase Inhibitor PCI-32765, a potential oral treatment for autoimmune diseases and lymphomas based on its ability to inhibit the activation of B-cells.